Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus.
about
Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma.Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study.Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer.
P2860
Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Cost-effectiveness of sorafeni ...... a payer perspective in Cyprus.
@en
Cost-effectiveness of sorafeni ...... a payer perspective in Cyprus.
@nl
type
label
Cost-effectiveness of sorafeni ...... a payer perspective in Cyprus.
@en
Cost-effectiveness of sorafeni ...... a payer perspective in Cyprus.
@nl
prefLabel
Cost-effectiveness of sorafeni ...... a payer perspective in Cyprus.
@en
Cost-effectiveness of sorafeni ...... a payer perspective in Cyprus.
@nl
P2860
P1476
Cost-effectiveness of sorafeni ...... a payer perspective in Cyprus.
@en
P2093
Panagiotis Ke Petrou
P2860
P304
P356
10.1586/14737167.2014.873703
P577
2014-01-07T00:00:00Z